Prevnar

BIOLOGICAL13 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), GlaxoSmithKline, CIHR Canadian HIV Trials Network, University of Melbourne, VA Office of Research and Development

Conditions

EncephalitisFallopian Tube CancerHaemophilus Influenzae Type bInfections, RotavirusInfections, Streptococcus PneumoniaeNeisseria MeningitidisOvarian CancerPneumococcal Infection

Phase 1

Early Versus Delayed Pneumococcal Vaccination in HIV

CompletedNCT00137605

CIHR Canadian HIV Trials NetworkPneumococcal Infections

Start: 2004-09-30End: 2007-10-31Updated: 2014-02-13

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

TerminatedNCT01312389

Abramson Cancer Center at Penn MedicineFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer

Start: 2011-04-30End: 2012-08-17Updated: 2021-11-15

Study of Gamma PN3 in the Elderly

CompletedNCT06562790

GPN VaccinesPneumonia, Pneumococcal

Start: 2024-08-26End: 2025-03-31Updated: 2025-05-11

Phase 2

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

CompletedNCT00129129

GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis

Start: 2004-08-01End: 2006-03-29Updated: 2018-08-24

Pneumococcal Vaccination of Fiji Infants

CompletedNCT00170612

University of MelbournePneumococcal Infections

Start: 2005-11-30End: 2008-08-31Updated: 2008-10-21

Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.

CompletedNCT00729001

GlaxoSmithKlineInfections, Rotavirus

Start: 2000-11-30End: 2002-09-30Updated: 2016-09-16

Phase 3

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

CompletedNCT00289783

GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis

Start: 2006-02-22End: 2008-02-26Updated: 2018-08-24

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

CompletedNCT00345683

GlaxoSmithKlineHaemophilus Influenzae Type b, Neisseria Meningitidis

Start: 2007-07-31End: 2008-11-30Updated: 2016-11-29

Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar

CompletedNCT00594347

Sanofi Pasteur, a Sanofi CompanyStreptococcus Pneumoniae

Start: 2007-11-30End: 2009-04-30Updated: 2015-06-18

Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population

CompletedNCT01041573

Valneva Austria GmbHEncephalitis

Start: 2010-03-31End: 2011-07-31Updated: 2021-07-27

Phase 4

Antibody Production in Immune Disorders

TerminatedNCT00023504

National Institute of Allergy and Infectious Diseases (NIAID)Primary Immune Deficiency

Start: 2002-06-13End: 2021-10-14Updated: 2021-10-15

Humoral Determinants of Immunity to Pneumococcal Infection

CompletedNCT00304382

VA Office of Research and DevelopmentInfections, Streptococcus Pneumoniae, Pneumococcal Infections, Pneumonia

Start: 2003-01-01End: 2012-06-01Updated: 2017-09-05

Unknown Phase

Systems Biology of PNEUMOVAX®23 and PREVNAR 13®

CompletedNCT01307449

Emory UniversityPneumococcal Infection

Start: 2014-04-30End: 2017-07-31Updated: 2018-10-02

Related Papers

Serologic response to porcine circovirus type 1 (PCV1) in infants vaccinated with the human rotavirus vaccine, <i>Rotarix</i>™: A retrospective laboratory analysis

Human Vaccines & Immunotherapeutics2016-09-228 citations

Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials.

2012-08-017 citations

The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY).

2012-02-139 citations